Might the EPO’s Enlarged Board of Appeal step into the CRISPR patent battle and reconsider the “all applicants” approach?

Jakob Wested, Timo Minssen, Esther Van Zimmeren

Publikation: AndetUdgivelser på nettet - Net-publikationFormidling

Abstract

The Broad Institute is facing a formidable task in defending the revoked CRISPR patent claims in their pending appeal at the EPO. Ultimately, some of the issues might still be referred to the Enlarged Board of Appeal. However, this might require a significant amount of legal and rhetorical agility.
OriginalsprogEngelsk
Publikationsdatojul. 2018
UdgiverHarvard Law School's Bill of Health blog
StatusUdgivet - jul. 2018

Citationsformater